AstraZeneca plc (NYSE:AZN) – Stock analysts at Jefferies Group boosted their FY2017 earnings per share (EPS) estimates for AstraZeneca in a research report issued on Tuesday. Jefferies Group analyst J. Holford now anticipates that the company will post earnings per share of $1.88 for the year, up from their prior estimate of $1.85.
AZN has been the subject of several other research reports. Citigroup raised shares of AstraZeneca to a “buy” rating in a report on Wednesday, October 18th. Zacks Investment Research lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. BMO Capital Markets set a $38.00 target price on shares of AstraZeneca and gave the stock a “buy” rating in a report on Tuesday, October 31st. Sanford C. Bernstein raised shares of AstraZeneca from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $30.00 to $39.00 in a report on Friday, September 22nd. Finally, JPMorgan Chase & Co. raised shares of AstraZeneca from a “neutral” rating to an “overweight” rating in a report on Friday, December 29th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $34.48.
AstraZeneca (NYSE:AZN) last issued its quarterly earnings results on Thursday, November 9th. The company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.57 by $0.55. The company had revenue of $6.23 billion during the quarter, compared to analyst estimates of $6 billion. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The firm’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.32 EPS.
Several institutional investors and hedge funds have recently made changes to their positions in AZN. WFG Advisors LP grew its holdings in shares of AstraZeneca by 36.0% in the second quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock valued at $127,000 after purchasing an additional 984 shares during the period. Valeo Financial Advisors LLC purchased a new stake in shares of AstraZeneca in the third quarter valued at about $133,000. Quadrant Capital Group LLC grew its holdings in shares of AstraZeneca by 18.4% in the second quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock valued at $147,000 after purchasing an additional 846 shares during the period. Wealthcare Advisory Partners LLC purchased a new stake in shares of AstraZeneca in the third quarter valued at about $184,000. Finally, FTB Advisors Inc. grew its holdings in shares of AstraZeneca by 3.2% in the second quarter. FTB Advisors Inc. now owns 6,471 shares of the company’s stock valued at $197,000 after purchasing an additional 200 shares during the period. 14.75% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “FY2017 EPS Estimates for AstraZeneca plc (AZN) Boosted by Jefferies Group” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://sportsperspectives.com/2018/01/19/fy2017-eps-estimates-for-astrazeneca-plc-azn-boosted-by-jefferies-group.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.